Nucleai is Leading the Spatial Biology Revolution in Precision Medicine
Transforming Precision Medicine Powered by AI-pathology
Scroll For More
We are committed to bringing the power of spatial biology to reality by providing pharmaceutical companies and clinicians with AI-powered image analysis applications. Our platform enhances drug development, supports treatment decisions and improves patient lives.
Our image analysis and biomarker discovery technology leverages real-world pathology, clinical and molecular datasets to better understand cancer biology, optimize patient stratification and improve patient care.
Gaining access to millions of annotated cells across 10+ cancer indications.
Analyzing pathology slides
Our algorithms detect and characterize tissue and cell architecture.
Cell & area locations are intersected to compute over hundreds of complex feature values.
Deep-learning models combining spatial features and clinical data drive the discovery of pathology-based spatial biomarkers.
Exploratory Research Platform
Our Platform empowers researchers to discover novel, human interpretable pathology-based biomarkers that predict response to therapy, identify genomic markers or explain complex biological phenomena at scale.
AI-Powered Clinical Trial Assays
Qualified biomarkers are incorporated into prospective clinical trials via Nucleai's AI-powered digital assays. In partnership with CROs and central laboratories, we support a compliant (FDA, CLIA, GxP) and scalable patient selection process.
Companion Diagnostics Development
In partnership with biopharma, diagnostics and clinical laboratories, we develop and deploy Nucleai's digital assays as companion diagnostics across the world, providing physicians with the best diagnostic tools to improve patient lives.
Nucleai’s platform unlocks spatial insights. In Nucleai Atom, your pathology slides are transformed into raw data of cell and area locations. The raw data is fed into the Nucleai engine, computing hundreds of spatial features intersected with outcome to predict drug response.
We are transforming precision medicine with AI-powered pathology
Our team’s work is a unique collaboration of experienced AI technologists, physicians and exceptional healthcare research professionals.
DATA & INSTITUTIONAL PARTNERS
Predicting Response to Pembrolizumab in NSCLC Using AI-pathology
At Nucleai, we bring physicians and researchers cutting edge AI-based technology that identifies pathology-based biomarkers that can predict response to therapy and significantly improve patient outcomes. Come join our team of experienced AI engineers, world renowned clinicians, and others, to revolutionize precision medicine and make a major impact.
Nucleai and Debiopharm Launch Research Collaboration Utilizing Nucleai's Ai-Powered Biomarker Platform
Nucleai's pathology-based platform analyzes tissue images using computer vision and machine learning methods to model the tumor and the immune system's spatial characteristics, creating unique and specific histological biomarkers that can predict patient response.
How AI Helps Advance Immunotherapy And Precision Medicine
While immunotherapies have revolutionized cancer treatment, they are currently effective only for a small subset (from 20% to 30%) of patients. Tel-Aviv-based Nucleai is developing AI software for image analysis and modeling of pathology data to assist in the development of more effective drugs.